NCT01650129View on ClinicalTrials.gov

Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

December 13, 2000

Primary Completion Date

October 18, 2001

Study Completion Date

October 18, 2001

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart 50

Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected immediately before breakfast and dinner

DRUG

biphasic human insulin 50

Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected 30 minutes before breakfast and dinner

Trial Locations (1)

1000005

Novo Nordisk Investigational Site, Tokyo

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01650129 - Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter